HEARTS & MINDS Lowering Cholesterol with Plant Stanol Ester Opening Remarks Herbert Schuster, M.D., Ph.D. Humboldt University Berlin, Berlin, Germany.

Slides:



Advertisements
Similar presentations
ATP III Guidelines Specific Dyslipidemias. 2 Specific Dyslipidemias: Very High LDL Cholesterol (  190 mg/dL) Causes and Diagnosis Genetic disorders –Monogenic.
Advertisements

Plant stanol ester in the treatment and prevention guidelines 0.
Lowering cholesterol – The earlier the better, the lower the better
CHOLESTEROL AND OUR LIVES الدهنيات وحياتنا
New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.
Lipid Disorders and Management in Diabetes
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Final Exam Tuesday, 6/5, 2 PM Closed book – Essay and MC/TF Determining Energy Needs – p – Indirect calorimetry – Be able to do the calculations.
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL)
Adult Treatment Panel III (ATP III) Guidelines
The Science of Plant Stanol Ester. Contents Background Plant stanol ester and LDL-cholesterol lowering Dose-response of plant stanol ester with high daily.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Role of Rosuvastatin in the Treatment of Dyslipidemia
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
Hyperlipidemia John Baer.
Department of Family & Community Medicine
Modern Management of Cholesterol in the High-Risk Patient.
Nutrition & Heart Disease Key Concepts and Facts Heart disease is leading cause of death Dietary and lifestyle factors are important Diets that provide.
The concept of Diabetes & CV risk: A lifetime risk challenge The Clinical Significance of LDL-Cholesterol: No Longer a Hypothesis? John J.P. Kastelein,
Hypertension, Cardiovascular Disease, Diabetes. 34% of Americans 36% of Americans.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Copyright® Raisio The effect of a very high daily plant stanol ester intake on serum lipids, carotenoids, and fat-soluble vitamins Gylling et.
Copyright® Raisio A plant stanol yogurt drink alone or combined with a low-dose statin lowers serum triacylglycerol and non-HDL cholesterol.
Dyslipidemia.  Dyslipidemia is elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high- density lipoprotein level that contributes.
ATP III Guidelines Therapeutic Lifestyle Changes (TLC)
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
Copyright® Raisio Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced.
Hyperlipidaemiák Szollár Lajos Klinikai kórélettan Szeptember 28.
Adult Treatment Panel III (ATP III) Guidelines Hyperlipidemia.
Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:
Fat or Low-fat? Anwar T. Merchant ScD, MPH, DMD Department of Epidemiology and Biostatistics.
Plant stanol esters in human studies Professor Helena Gylling University of Kuopio.
Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Next Steps in Primary Prevention of Coronary Heart.
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
NICE –CG 181 Continuum of CVD Risk and its treatment
Therapeutic Lifestyle
Challenges Facing Lipid Guidelines
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Plant stanol esters in low-fat yogurt reduces total and low-density lipoprotein cholesterol and low-density lipoprotein oxidation in normocholesterolemic.
2013 ACC/AHA cholesterol treatment guidelines
Pravastatin in Elderly Individuals at Risk of Vascular Disease
Phenotype vs. Genotype: Defining Severe Familial Hypercholesterolemia
Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Louise Bowman & Martin Landray on.
Triglycerides Cholesterol HDL-C or N NIDDM N or or N IDDM.
AIM HIGH Niacin plus Statin to prevent vascular events
HDL cholesterol and cardiovascular risk Epidemiological evidence
First time a CETP inhibitor shows reduction of serious CV events
Lipids in Health and Disease
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Cardiovascular System
National Cholesterol Education Program
HDL cholesterol and cardiovascular risk
FATS- Familial Atherosclerosis Treatment Study
Lipids in Health and Disease
NCEP/Framingham risk scores: Estimate of 10-yr CHD risk in men without CHD VBWG Age (y) 20–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79.
Baseline characteristics of HPS participants by prior diabetes
Case 1: A 73-year-old white female with carotid disease
Jonathan C. Cohen, PhD  Journal of Clinical Lipidology 
2013 ACC/AHA cholesterol treatment guidelines
Lipids in Health and Disease
Chapter 7 LIPIDS IN HEALTH & DISEASE
Goals & Guidelines A summary of international guidelines for CHD
Cause of death Treatment-arm events, % (n=45 054)
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Presentation transcript:

HEARTS & MINDS Lowering Cholesterol with Plant Stanol Ester Opening Remarks Herbert Schuster, M.D., Ph.D. Humboldt University Berlin, Berlin, Germany Chairman

AGENDA Organizational Issues Introduction Programme Overview

International Cardiovascular Disease Statistics 2005; AHA. Global Burden of Cardiovascular Disease In 2002: CVD contributed to approximately a third of all global deaths (17 million) 80% of burden is in low- and middle-income countries By 2020: CHD and stroke will become the leading cause of death and disability worldwide Mortality from CVD will increase to 20 million CVD lowers quality of life but clinical care is also costly

Environmental Risk Factors Illustrated by Peter Breugel

Lifestyle Changes are the Basic Principle of Cardiovascular Risk Prevention Oslo Diet Heart Study 412 men with CHD, 5 year controlled trial Treatment group randomized to low saturated fat, low cholesterol, high polyunsaturated fat diet Serum cholesterol reduced by 14% 33% reduction in myocardial infarction, 26% decrease in coronary heart disease mortality Leren et al. Acta Med Scand 1966; 466:1

Lifestyle Changes are the Basic Principle of Cardiovascular Risk Prevention Lifestyle Heart Trial 41 male and female CHD patients Randomized to <10% fat diet, exercise and meditation (Rx group) versus Step 1 diet At one year 37% LDL-Cholesterol reduction, 22% weight loss, and 1.8% regression in Rx group versus 2.3 progression in control group (quantitative coronary angiography) At 5 years 20% LDL-Cholesterol reduction, 3.1% regression in Rx groups versus 11.8% progression in control group (n=35) Ornish et al. Lancet 1990; 336: , and JAMA 1998; 280:

Major coronary events Major vascular events Prospective meta-analysis of data from participants in 14 randomized statin trials CTT Collaborators. Lancet. 2005;366:1267–78. Proportional reduction in event rate (%  SE) Reduction in LDL-C in mmol/l (mg/dl) (19) 1.0 (38) 1.5 (58) 2.0 (77) 0.5 (19) 1.0 (38) 1.5 (58) 2.0 (77) Statin Trials Reinforce the Need to Consider Substantial LDL-Cholesterol Reduction

Grundy SM et al. Circulation. 2004;110: * Therapeutic option mg/dl= 1.8 mmol/l; 100 mg/dl= 2.6 mmol/l; 130 mg/dl= 3.4 mmol/l; 160 mg/dl= 4.1 mmol/l LDL-C level [mg/dl] CHD or CHD risk equivalents High Risk ≥2 risk factors Moderately High Risk ≥ 2 risk factors Moderate Risk <2 risk factors Lower Risk (10-yr risk >20%)(10-yr risk 10-20%)(10-yr risk <10%) Goal 100 mg/dl or optional 70 mg/dl* or optional 100 mg/dl* Goal 130 mg/dl Goal 160 mg/dl Existing LDL-C goals Proposed LDL-C goals Goal 130 mg/dl NCEP ATP III: LDL-C Goals Including 2004 Proposed Modifications

Key Questions in Cardiovascular Disease Prevention HOW LOW SHOULD WE GO? HOW EARLY SHOULD WE START?

th Percentile Sequence variants in the PCSK9 gene increase levels of LDL receptors in the liver Frequency (%) Cohen C et al. N Engl J Med. 2006;354: No PCSK9 46L Allele (N=9223) PCSK9 46L Allele (N=301) Plasma LDL-Cholesterol in white subjects (mg/dl) (mean age 54 years) Subjects with a PCSK9 Gene Variant have a 15% Lifelong Reduction in LDL-Cholesterol

Cohen C et al. N Engl J Med. 2006;354: Coronary Heart Disease (%) NoYes Subjects with the mean age of 54 years with the PCSK9 sequence variation have a significant 47% CHD risk reduction (hazard ratio 0.50; 95% confidence interval 0.32 to 0.79; p=0.003) p=0.003 PCSK9 46L Lifelong Reduction of LDL-Cholesterol is Associated with a Reduction of Coronary Events

Research History on Plant Stanols and Sterols  Early 1950s to 1980s  Focus on sterols  Mid 1980s  Shift of focus from sterols to stanols  The 1990s  Focus on sterol and stanol esters as food ingredients  2000 to present  Low-fat food forms Plant Stanol Ester Containing Functional Food A New Option for Cholesterol Lowering

Lowering Cholesterol with Plant Stanol Ester Facts, Figures, Actions 10:30Klaus von Bergmann “Absorption, distribution, and elimination of plant sterols in humans” 11:00Helena Gylling “Plant stanol esters in human studies” 11:30Coffee 12:00Joghum Plat “Plant stanol and sterol esters - mechanisms and safety issues” 12:30Albert Wiegman “Children with familial hypercholesterolemia – Cardiovascular risk prevention” 13:00Discussion 13:30Lunch

HEARTS & MINDS Lowering Cholesterol with Plant Stanol Ester Closing Remarks Herbert Schuster, M.D., Ph.D. Humboldt University Berlin, Berlin, Germany Chairman

Plant Stanol Ester in Clinical Trials Summary (1) Over 40 clinical trials show that 2-3 grams of stanol ester lower... serum total cholesterol by about 10% serum LDL cholesterol by up to 15% serum plant sterols 30-50% does not affect HDL or TG

Plant Stanol Ester in Clinical Trials Summary (2) Stanol ester reduces serum cholesterol concentration... effectively long-term additive with other dietary changes additive with statins in diabetics in patients with metabolic syndrome in adults and children

Plant Stanol Ester are Included in Dyslipidemia Treatment Guidelines US National Cholesterol Education Program TLC diet Reference: JAMA: 2001;285: Reduced intake of cholesterol-raising nutrients LDL-lowering therapeutic options + Plant stanols/sterols (2 g per day) Viscous (soluble) fiber (10–25 g per day) International Atherosclerosis Society, 2003 International Lipid Information Bureau, in Dyslipidemia and Coronary Heart Disease, 3rd edition 2003, eds Gotto AM, Amarenco P, Assmann G, Carmena R, Davignon J, Fruchart JC, Kastelein JJP, Paoletti R, Tonkin A National guidelines, e.g. Käypä Hoito in Finland